Fundraising Fox
ImmunoVec
Los Angeles, US · Founded 2019 · 12 employees on LinkedIn · 3 known investors
Find your way into ImmunoVec
Sign up to see every warm intro you have to ImmunoVec
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ImmunoVec team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ImmunoVec develops programmable DNA-based in vivo medicines that use cell type- and cell state-specific synthetic promoters to control payload expression in targeted cells for treating cancer and autoimmune disease. Its expression cassettes can be incorporated into both viral and non-viral delivery vehicles such as lentivirus, AAV, lipid and polymeric nanoparticles, and exosomes.
Founders & leadership
ImmunoVec was founded in 2019 by Dillon Woodward.
Board
Investors · 3
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$17M disclosed across 2 of 3 rounds · 2021–2026
▶$12.7MraisedJul 2026 · 10 investors · Other TechnologyRule 506(b)
- Ryan WongExecutive Officer, Director
- William WoodwardExecutive Officer, Director
- Douglass LorenzenExecutive Officer, Director, Promoter
- Chris LucasDirector
- Offering amount
- $15M
- Amount sold
- $12.7M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.3MraisedMar 2022 · 25 investors · Other TechnologyRule 506(b)
- Dillon WoodwardDirector
- William WoodwardExecutive Officer, Director, Promoter
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does ImmunoVec do?
- ImmunoVec develops programmable DNA-based in vivo medicines that use cell type- and cell state-specific synthetic promoters to control payload expression in targeted cells for treating cancer and autoimmune disease. Its expression cassettes can be incorporated into both viral and non-viral delivery vehicles such as lentivirus, AAV, lipid and polymeric nanoparticles, and exosomes.
- Who founded ImmunoVec?
- ImmunoVec was founded by Dillon Woodward in 2019.
- Who are ImmunoVec's investors?
- ImmunoVec's investors include Anthem Venture Management, Llc, Ying Fund.
- How much funding has ImmunoVec raised?
- ImmunoVec has disclosed $17M raised across 2 of its 3 known rounds.
- Where is ImmunoVec headquartered?
- ImmunoVec is headquartered in Los Angeles, US.